Acasti Pharma’s QQ1 2026 results depict a quintessential early-stage biotechnology profile: no reported revenue for the quarter, continued operating losses, and a cash burn driven primarily by research and development and administrative expenses. The company posted an EBITDA of -$3.36 million and an operating loss of -$3.09 million for the quarter, with net income of -$3.362 million and basic earnings per share of -$0.21. Cash provided by operating activities was negative at -$1.801 million, contributing to a net decrease in cash of -$2.128 million for the period, leaving cash and equivalents of $20.005 million at period end. Notably, the balance sheet shows a substantial stockholders’ equity base (~$63.55 million) and an absence of debt, with total assets of $69.805 million anchored by sizable intangible assets ($41.128 million) and goodwill ($8.138 million). Retained earnings remain deeply negative (~$224.049 million), underscoring cumulative burn and the developmental stage of the portfolio.